Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Benitec Biopharma Ltd (NASDAQ: BNTC).

Full DD Report for BNTC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BNTC)

Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting
SYDNEY , May 15, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) today announced that data from its oculopharyngeal muscular dystrophy (OPMD) program will be presented at the American Society of Gene and Cell Therapy (ASGCT) meeting being held in ...
Source: PR Newswire
Date: May, 15 2018 08:00
Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program
SYDNEY , May 3, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it will host a conference call and webcast for investors and analysts on 15 May 2018 at 4:30pm U.S. EST / 16 May 2018 at 6:30am Australian EST. ...
Source: PR Newswire
Date: May, 03 2018 08:00
Midday Gainers / Losers (04/30/2018)
Gainers:  STDY +78% . FNGN +32% . CHEK +31% . ATOS +21% . HTBX +18% . ASNS +16% . FDC +15% . ANDV +13% . IRMD +13% . AQ +12% . More news on: SteadyMed, Financial Engines, Inc., Check-Cap Ltd., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 30 2018 12:49
ASX/NASDAQ Announcement
SYDNEY , April 24, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD).  This update should be read...
Source: PR Newswire
Date: April, 24 2018 08:00
Novartis takeout of AveXis stokes buying in gene therapy players
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up  8%  and  10%  premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In...
Source: SeekingAlpha
Date: April, 09 2018 07:19
RNAi For Hepatitis B - A False Hope For A Cure?
Editor's note: Seeking Alpha is proud to welcome BZ Equity Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Hepat...
Source: SeekingAlpha
Date: April, 06 2018 14:59
Your Daily Pharma Scoop: Genocea Surges, Gilead's Biktarvy, GlaxoSmithKline's Vaccine Succeeds In Late-Stage Study
Analysis of top Seeking Alpha coverage: Genocea Biosciences Today, we will discuss Genocea Biosciences (GNCA), which is up sharply after a bullish note from Cantor Fitzgerald. In early trading, GNCA shares were up nearly 10%, offsetting some of the losses the company has incurred in 2018. Ye...
Source: SeekingAlpha
Date: March, 07 2018 08:00
Benitec launches mid-stage study of BB-401 in HNSCC; shares up 4%
Thinly traded nano cap Benitec Biopharma ( BNTC +4.2% ) commences an Australia and Russia-based Phase 2 clinical trial evaluating BB-401 in patients with head and neck squamous cell carcinoma (HNSCC). More news on: Benitec, Healthcare stocks news, Stocks on the move, Read more .....
Source: SeekingAlpha
Date: March, 05 2018 13:02
Benitec Biopharma Launches its Phase 2 Oncology Study in Australia
SYDNEY , March 5, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named dd...
Source: PR Newswire
Date: March, 05 2018 08:00
Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
SYDNEY , Feb. 22, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-silencing technology call...
Source: PR Newswire
Date: February, 22 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-212.652.652.702.6358,670
2018-08-202.682.652.722.654,195
2018-08-172.682.682.682.66910
2018-08-162.782.682.782.67014,513
2018-08-152.672.812.812.664,275

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-214004,6308.6393Cover
2018-08-208213,32124.7215Cover
2018-08-161001,7785.6243Cover
2018-08-131001,6006.2500Cover
2018-08-102,55010,07925.3001Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BNTC.


About Benitec Biopharma Ltd (NASDAQ: BNTC)

Logo for Benitec Biopharma Ltd (NASDAQ: BNTC)

Not available

 

Contact Information

 

 

Current Management

  • Peter French / CEO, Managing Director
  • Greg West / Secretary

Current Share Structure

     


    Recent Filings from (NASDAQ: BNTC)

    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: May, 09 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 03 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: May, 01 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 01 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 24 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 22 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 22 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: January, 30 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: January, 23 2018

     

     


    Daily Technical Chart for (NASDAQ: BNTC)

    Daily Technical Chart for (NASDAQ: BNTC)


    Stay tuned for daily updates and more on (NASDAQ: BNTC)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: BNTC)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BNTC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BNTC and does not buy, sell, or trade any shares of BNTC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/